c‑Jun N‑terminal kinase 3 signalling serves a potential role as a biomarker for determining the pathogenesis of Parkinson's disease

Yang,Xiu‑Li; Gao,Chun‑Mei

doi:10.3892/mmr.2017.8244

c‑Jun N‑terminal kinase 3 signalling serves a potential role as a biomarker for determining the pathogenesis of Parkinson's disease

Authors:
- Xiu‑Li Yang
- Chun‑Mei Gao
View Affiliations

Affiliations: The Department of Blood Transfusion, The First People's Hospital of Shangqiu, Shangqiu, Henan 476100, P.R. China
Published online on: December 11, 2017 https://doi.org/10.3892/mmr.2017.8244
Pages: 3255-3259

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Parkinson's disease (PD) is a movement-associated disorder that specifically affects dopamine-producing neurons. The disease causes demyelation that adversely impacts upon the motor activity of the brain. Currently there are no promising biomarkers for PD; improved understanding of the molecular mechanisms underlying the different pathological stages of PD are required to enable identification of a novel biomarker. The present study successfully established a PD mouse model via nasal injection of 1‑methyl-4‑phenyl-1,2,3,6-tetrahydropyridine. The expression of c‑Jun N‑termal kinase 3 (JNK3) and caspase‑3 in two different pathological stages of PD were analysed using immunohistochemistry and western blot analysis. The results inidcated that the initial PD pathogenesis recovers on response to rasagiline. Immunohistochemistry and western blot analysis revealed that treatment with rasagiline positively regulated early‑stage PD pathogenesis by downregulating the expression of JNK3 and upregulating caspase‑3; however, there was no positive effect on the advanced stages of PD. Overall, these results concluded that rasagiline has the ability to inhibit the expression of JNK3 and upregulate caspase‑3 in early stages of PD; however, rasagline appears to have no impact on JNK3 and caspase‑3 levels in the advanced stages of PD.

View Figures

View References

1	AlDakheel A, Kalia LV and Lang AE: Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics. 11:6–23. 2014. View Article : Google Scholar : PubMed/NCBI
2	Buter TC, Van den Hout A, Matthews FE, Larsen JP, Brayne C and Aarsland D: Dementia and survival in Parkinson disease: A 12-year population study. Neurology. 70:1017–1022. 2008. View Article : Google Scholar : PubMed/NCBI
3	Crabtree D: Modulation of alpha-synuclein metabolism and toxicity by cathepsin D. Uni Alabama Birmingham; 2012
4	Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM and Evans DA: Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med. 334:71–76. 1996. View Article : Google Scholar : PubMed/NCBI
5	Kish SJ, Shannak K, Rajput A, Deck JH and Hornykiewicz O: Aging produces a specific pattern of striatal dopamine loss: Implications for the etiology of idiopathic Parkinson's disease. J Neurochem. 58:642–648. 1992. View Article : Google Scholar : PubMed/NCBI
6	Hornykiewicz O: Ageing and neurotoxins as causative factors in idiopathic Parkinson's disease-a critical analysis of the neurochemical evidence. Prog Neuropsychopharmacol Biol Psychiatry. 13:319–328. 1989. View Article : Google Scholar : PubMed/NCBI
7	Lang AE: Clinical trials of disease-modifying therapies for neurodegenerative diseases: The challenges and the future. Nat Med. 16:1223–1226. 2010. View Article : Google Scholar : PubMed/NCBI
8	Schapira AH: Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol. 26:395–400. 2013. View Article : Google Scholar : PubMed/NCBI
9	Schapira AH and Schrag A: Parkinson disease: Parkinson disease clinical subtypes and their implications. Nat Rev Neurol. 7:247–248. 2011. View Article : Google Scholar : PubMed/NCBI
10	Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, et al: Movement disorder society-sponsored revision of the unified parkinson's disease rating scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord. 23:2129–2170. 2008. View Article : Google Scholar : PubMed/NCBI
11	Kyriakis JM and Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 81:807–869. 2001.PubMed/NCBI
12	Dhanasekaran DN and Reddy EP: JNK signaling in apoptosis. Oncogene. 27:6245–6251. 2008. View Article : Google Scholar : PubMed/NCBI
13	Bogoyevitch MA: The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): Differences revealed by gene targeting. Bioessays. 28:923–934. 2006. View Article : Google Scholar : PubMed/NCBI
14	Prediger RD, Aguiar AS Jr, Moreira EL, Matheus FC, Castro AA, Walz R, De Bem AF, Latini A, Tasca CI, Farina M and Raisman-Vozari R: The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A new rodent model to test palliative and neuroprotective agents for Parkinson's disease. Curr Pharm Des. 17:489–507. 2011. View Article : Google Scholar : PubMed/NCBI
15	Duty S and Jenner P: Animal models of Parkinson's disease: A source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 164:1357–1391. 2011. View Article : Google Scholar : PubMed/NCBI
16	Su JH, Anderson AJ, Cummings BJ and Cotman CW: Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport. 5:2529–2533. 1994. View Article : Google Scholar : PubMed/NCBI
17	Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA. 76:pp. 4350–4354. 1979; View Article : Google Scholar : PubMed/NCBI
18	Vlahopoulos S and Zoumpourlis VC: JNK: A key modulator of intracellular signaling. Biochemistry (Mosc). 69:844–854. 2004. View Article : Google Scholar : PubMed/NCBI
19	Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C and Berecz G; Rasagiline Study Group, : Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 23:324–330. 2000. View Article : Google Scholar : PubMed/NCBI
20	King KL and Cidlowski JA: Cell cycle regulation and apoptosis 1. Annu Rev Physiol. 60:601–617. 1998. View Article : Google Scholar : PubMed/NCBI
21	Hanyu H, Asano T, Sakurai H, Takasaki M, Shindo H and Abe K: Magnetisation transfer measurements of the subcortical grey and white matter in Parkinson's disease with and without dementia and in progressive supranuclear palsy. Neuroradiology. 43:542–546. 2001. View Article : Google Scholar : PubMed/NCBI
22	Donovan S: Parkinson's disease treatment US 6620415 B2. Filed July 11, 2001; issued September 16. 2003
23	Wegner C and Stadelmann C: Gray matter pathology and multiple sclerosis. Curr Neurol Neurosci Rep. 9:399–404. 2009. View Article : Google Scholar : PubMed/NCBI
24	Rathinam R, Berrier A and Alahari SK: Role of Rho GTPases and their regulators in cancer progression. Front Biosci (Landmark Ed). 16:2561–2571. 2011. View Article : Google Scholar : PubMed/NCBI
25	Cellurale C, Girnius N, Jiang F, Cavanagh-Kyros J, Lu S, Garlick DS, Mercurio AM and Davis RJ: Role of JNK in mammary gland development and breast cancer. Cancer Res. 72:472–481. 2012. View Article : Google Scholar : PubMed/NCBI
26	Bellamy CO, Malcolmson RD, Harrison DJ and Wyllie AH: Cell death in health and disease: The biology and regulation of apoptosis. Semin Cancer Biol. 6:3–16. 1995. View Article : Google Scholar : PubMed/NCBI